Silexion Therapeutics Corp Financials
Silexion Therapeutics Corp (SLXN) reported $155K in revenue for fiscal year 2025, up 453.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not revenue, is the engine keeping this development-stage business liquid while R&D drives losses.
Between FY2024 and FY2025, liquidity improved sharply: cash rose from$1.2M to$6.0M and the current ratio moved from 0.6x to 2.4x, but that repair came from financing inflows of$15.6M , not from operations, which used$10.8M of cash in FY2025. The balance sheet got healthier even as the business remained structurally pre-revenue.
Cash use is almost entirely operating, not capital spending: free cash flow and operating cash flow were nearly identical across the last three fiscal years, with capex only
The expense mix shifted toward R&D in FY2025: research spending rose to
Financial Health Signals
Silexion Therapeutics Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Silexion Therapeutics Corp scores -15.28, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($569K) relative to total liabilities ($4.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Silexion Therapeutics Corp passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Silexion Therapeutics Corp reported a net loss of $11.9M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Silexion Therapeutics Corp reported an operating loss of $11.6M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Silexion Therapeutics Corp generated $155K in revenue in fiscal year 2025. This represents an increase of 453.6% from the prior year.
Silexion Therapeutics Corp's EBITDA was -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.4% from the prior year.
Silexion Therapeutics Corp reported -$11.9M in net income in fiscal year 2025.
Silexion Therapeutics Corp earned $89.61 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 97.7% from the prior year.
Cash & Balance Sheet
Silexion Therapeutics Corp recorded an outflow of $10.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 28.6% from the prior year.
Silexion Therapeutics Corp held $6.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Silexion Therapeutics Corp's ROE was -457.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Silexion Therapeutics Corp invested $7.1M in research and development in fiscal year 2025. This represents an increase of 22.8% from the prior year.
Silexion Therapeutics Corp invested $9K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 59.1% from the prior year.
Not reported for fiscal year 2025.
SLXN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $185K | $155K+453.6% | $28K-81.7% | $153K |
| R&D Expenses | $7.9M | $7.1M+22.8% | $5.8M+56.8% | $3.7M |
| SG&A Expenses | $4.8M | $4.5M-33.5% | $6.8M+594.3% | $973K |
| Operating Income | -$12.7M | -$11.6M+7.5% | -$12.6M-168.6% | -$4.7M |
| Interest Expense | $2K | $13K-51.9% | $27K | $0 |
| Income Tax | N/A | $3K-70.0% | $10K-68.8% | $32K |
| Net Income | -$12.9M | -$11.9M | N/A | -$5.1M |
| EPS (Diluted) | — | $89.61-97.7% | $3955.11+499.7% | $659.55 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SLXN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $7.2M+152.0% | $2.9M-45.5% | $5.3M |
| Current Assets | $6.6M+195.0% | $2.3M-54.8% | $5.0M |
| Cash & Equivalents | $6.0M+404.7% | $1.2M-74.2% | $4.6M |
| Total Liabilities | $4.6M-32.7% | $6.9M-66.9% | $20.7M |
| Current Liabilities | $2.8M-21.7% | $3.5M+60.4% | $2.2M |
| Total Equity | $2.6M+165.3% | -$4.0M+74.2% | -$15.5M |
| Retained Earnings | -$55.2M-27.5% | -$43.3M-61.3% | -$26.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
SLXN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$12.0M | -$10.8M-28.9% | -$8.4M-85.4% | -$4.5M |
| Capital Expenditures | $3K | $9K-59.1% | $22K+83.3% | $12K |
| Free Cash Flow | -$12.0M | -$10.8M-28.6% | -$8.4M-85.4% | -$4.5M |
| Investing Cash Flow | -$8K | -$14K+36.4% | -$22K-103.8% | $573K |
| Financing Cash Flow | $8.3M | $15.6M+206.4% | $5.1M+877.8% | $522K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SLXN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Operating Margin | -7504.5% | -44896.4% | -3059.5% |
| Net Margin | -7685.2% | N/A | -3338.6% |
| Return on Equity | -457.6% | N/A | N/A |
| Return on Assets | -165.1% | N/A | -97.2% |
| Current Ratio | 2.41+1.8x | 0.64-1.6x | 2.27 |
| Debt-to-Equity | 1.77 | N/A | N/A |
| FCF Margin | -6985.8% | -30064.3% | -2968.0% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Silexion Therapeutics Corp Ranks
Frequently Asked Questions
What is Silexion Therapeutics Corp's annual revenue?
Silexion Therapeutics Corp (SLXN) reported $155K in total revenue for fiscal year 2025. This represents a 453.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Silexion Therapeutics Corp's revenue growing?
Silexion Therapeutics Corp (SLXN) revenue grew by 453.6% year-over-year, from $28K to $155K in fiscal year 2025.
Is Silexion Therapeutics Corp profitable?
No, Silexion Therapeutics Corp (SLXN) reported a net income of -$11.9M in fiscal year 2025.
What is Silexion Therapeutics Corp's EBITDA?
Silexion Therapeutics Corp (SLXN) had EBITDA of -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Silexion Therapeutics Corp's return on equity (ROE)?
Silexion Therapeutics Corp (SLXN) has a return on equity of -457.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Silexion Therapeutics Corp's free cash flow?
Silexion Therapeutics Corp (SLXN) recorded an outflow of $10.8M in free cash flow during fiscal year 2025. This represents a -28.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Silexion Therapeutics Corp's operating cash flow?
Silexion Therapeutics Corp (SLXN) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Silexion Therapeutics Corp's total assets?
Silexion Therapeutics Corp (SLXN) had $7.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Silexion Therapeutics Corp's capital expenditures?
Silexion Therapeutics Corp (SLXN) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Silexion Therapeutics Corp spend on research and development?
Silexion Therapeutics Corp (SLXN) invested $7.1M in research and development during fiscal year 2025.
What is Silexion Therapeutics Corp's current ratio?
Silexion Therapeutics Corp (SLXN) had a current ratio of 2.41 as of fiscal year 2025, which is generally considered healthy.
What is Silexion Therapeutics Corp's debt-to-equity ratio?
Silexion Therapeutics Corp (SLXN) had a debt-to-equity ratio of 1.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Silexion Therapeutics Corp's return on assets (ROA)?
Silexion Therapeutics Corp (SLXN) had a return on assets of -165.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Silexion Therapeutics Corp's cash runway?
Based on fiscal year 2025 data, Silexion Therapeutics Corp (SLXN) had $6.0M in cash against an annual operating cash burn of $10.8M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Silexion Therapeutics Corp's Altman Z-Score?
Silexion Therapeutics Corp (SLXN) has an Altman Z-Score of -15.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Silexion Therapeutics Corp's Piotroski F-Score?
Silexion Therapeutics Corp (SLXN) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Silexion Therapeutics Corp's earnings high quality?
Silexion Therapeutics Corp (SLXN) reported a net loss of $11.9M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Silexion Therapeutics Corp cover its interest payments?
Silexion Therapeutics Corp (SLXN) reported an operating loss of $11.6M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.